Corpus Intelligence IC Memo — THE ORTHOPEDIC SPECIALTY HOSPITAL 2026-04-26 04:04 UTC
IC Memo — THE ORTHOPEDIC SPECIALTY HOSPITAL
Investment Committee Memorandum | UT | 40 beds | Grade C | EBITDA uplift $6.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE ORTHOPEDIC SPECIALTY HOSPITAL

CCN 460049 | SALT LAKE, UT | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

THE ORTHOPEDIC SPECIALTY HOSPITAL is a 40-bed suburban community hospital in SALT LAKE, UT with $88.7M in net patient revenue and a 12.4% operating margin. The hospital serves a payer mix of 22.8% Medicare, 0.6% Medicaid, and 76.6% commercial.

Thesis: Turnaround. Our ML models identify $6.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 12.4% to 19.7% (+736bps).

Net Revenue HCRIS$88.7M
Current EBITDA COMPUTED$11.0M
Operating Margin COMPUTED12.4%
Occupancy HCRIS4.6%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS42.6%
Distress Probability ML57.2%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
25
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 12.4% places it above the state median. Among 25 size-comparable peers (20-80 beds), the median margin is 4.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 25 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE ORTHOPEDIC SPECIALTY HOSPI (Target)UT40$88.7M12.4%
CEDAR CITY HOSPITALUT48$136.8M31.4%
LONE PEAK HOSPITALUT61$133.1M25.2%
ALTA VIEW HOSPITALUT57$130.9M-0.6%
GUNNISON VALLEY HOSPITALUT25$130.4M-6.4%
LAYTON HOSPITALUT37$121.1M9.5%
PARK CITY HOSPITALUT37$120.8M13.7%
UINTAH BASIN MEDICAL CENTERUT33$119.9M1.8%
MOUNTAIN WEST MEDICAL CENTERUT36$96.1M38.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.9M+210bp18mo
Cost to Collect4.5%2.5%$1.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.1M+122bp9mo
Clean Claim Rate88.0%96.0%$57K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.9M
Cost to Collect
$1.8M
Denial Rate Reduction
$1.8M
A/R Days Reduction
$1.1M
Clean Claim Rate
$57K
Total EBITDA Uplift$6.5M
Current EBITDA$11.0M
+ RCM Uplift+$6.5M
Pro Forma EBITDA$17.5M
Current Margin12.4%
Pro Forma Margin19.7%
WC Released (1x)$3.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$16.9M$137.7M8.16x52.2%
Base (11x exit)10.0x11.0x$16.9M$157.0M9.30x56.2%
Bull Case9.0x11.0x$15.2M$184.0M12.11x64.7%
Bull (12x exit)9.0x12.0x$15.2M$205.2M13.51x68.3%
Bear Case11.0x10.0x$18.6M$99.6M5.36x39.9%
Bear (11x exit)11.0x11.0x$18.6M$115.6M6.22x44.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 4.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 57.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 25 hospitals with 20-80 beds
  • Same-state prioritization (n=26)
  • Comp margins: P25=-12.4% / P50=4.3% / P75=15.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.